

Molecular Investigation of Extended-Spectrum β -Lactamase and Patterns of Antibiotic Resistance in *Enterobacter cloacae* Isolates from Teaching Hospitals in Kermanshah, Iran

MITRA HEMMATI¹, SIAVASH VAZIRI², MANDANA AFSHARIAN³, FAIZULLAH MANSOURI⁴, MOHAMMAD HOSSEIN ZAMANIAN⁵, SEPIDEH FERESHTEH⁶, KAMAL AHMADI⁷, MOHSEN AZIZI⁸

ABSTRACT

Introduction: *Enterobacter cloacae* are responsible for a variety of hospital acquired infections including sepsis and Urinary Tract Infection (UTI). High emergence rate of Extended Spectrum β -Lactam (ESBL) resistant bacteria has led to increased rates of mortality, therapeutic failure and healthcare expenses. Identification of Cefotaximase-Munich (CTX-M), Temoneira (TEM), and Sulphydrylvariable (SHV) genes can help in determining the epidemiology, and thereby aid in development of anti-microbial therapy.

Aim: To determine molecular frequency of ESBL in *E. cloacae* isolates obtained from Teaching Hospitals of Kermanshah, Iran.

Materials and Methods: The descriptive cross-sectional study was conducted from January 2017 to November 2017, and 93 *E. cloacae* isolates were collected. All isolates were identified by standard microbiological and biochemical methods including Triple Sugar Iron (TSI) and Indole, Methyl red, Voges-Proskauer, Citrate (IMViC) test. After identifying the resistance pattern of such isolates via Disc diffusion test (DDST), isolates were

evaluated for ESBLs using combination disc phenotypic method. Frequency of CTX-M, TEM, and SHV genes was investigated by Polymerase Chain Reaction (PCR). Chi-square and Fisher's-tests were used for statistical analysis. The p-values <0.05 were considered statistically significant.

Results: Maximum number of isolates were resistant to Amoxicillin-Clavulanic acid (97.8%), followed by Tetracycline and Ceftazidime (60.2%), and Colistin had the highest sensitivity (100%). Among them, 55 (59.1%) isolates had an ESBL phenotype and 65 (69.9%) of them were Multi-Drug Resistant (MDR). The frequency of CTX-M, TEM, and SHV genes was 26 (47.3%), 12 (21.8%) and 3 (5.5%), respectively. CTX-M was found to be resistance to Cefotaxime (p-value=0.038), Ceftazidime (p-value=0.046), and Imipenem (p-value=0.016), and TEM gene was resistant to Ceftazidime (p-value=0.024) and Chloramphenicol (p-value=0.019).

Conclusion: Increasing antibiotic-resistant in *E. cloacae* isolates is a serious concern for public health that warrants judicious use of antibiotics, and rapid identification of ESBL positive isolates.

Keywords: Antimicrobial therapy, β -lactams, Drug resistance, Polymerase chain reaction, Urinary tract infection

INTRODUCTION

Enterobacter is a gram-negative and facultative-anaerobe of genus Enterobacteriaceae family that is ubiquitous in the saprophytic form in nature, and is found in human intestinal tracts as normal flora [1,2]. This genus has 22 different identified species including *Enterobacter aerogenes*, *Enterobacter cloacae*, *Enterobacter helveticus* and *Enterobacter dissolvens* [3]. Like other Enterobacteriaceae family, *Enterobacter* genus is considered as an agent of nosocomial infections, especially opportunistic infections in immunocompromised and hospitalised patients [4]. Among its different species, *E. cloacae* can lead to 65-75% of *Enterobacter* infections, and it is also one of the most common isolated *Enterobacter* species from different clinical samples. As an opportunistic pathogen, *E. cloacae* often leads to various infections such as respiratory tract infection, urinary tract infection, skin problems, sepsis, soft tissue, endocarditis, pneumonia, septic arthritis, as well as osteomyelitis, especially in Intensive Care Units (ICU) [4,5]. The development of resistance in *Enterobacter* species has led to therapeutic failure in infection treatment process. Prolonged stay in hospital, exposure to different classes of antibiotics, particularly broad-spectrum cephalosporin, and use of central venous catheter are recognised as important risk factors for *E. cloacae* infections [6]. β -lactams are the most widely used medicines against *E. cloacae* infections; but its improper or overuse results in development of multi-drug resistant strains [7]. β -lactamase enzymes are the most significant mechanisms of

β -lactam resistance, that hydrolyzes the β -lactam ring and deactivates it. ESBL develop high rates of drug resistance and confine current antibiotic choices. Nosocomial infection of ESBL-producing bacteria also has high morbidity and mortality rates [8]. Literature suggests that the prevalence rate of ESBL-producing *Enterobacter* isolates is an increasing trend. The most common ESBL genes in different *Enterobacter* isolates are TEM, SHV, and CTX-M derivatives [9-11]. Given the high frequency of *E. cloacae* isolates taken from several clinical samples of teaching hospitals in the city of Kermanshah, Iran, and the absence of comprehensive studies about identifying the prevalence rate of broad-spectrum β -lactamase, the present study was designed to determine the molecular frequency of TEM, SHV, and CTX-M as well as drug resistance patterns in *E. cloacae* isolates collected from clinical samples of teaching hospitals in the city of Kermanshah, Iran.

MATERIALS AND METHODS

The present descriptive cross-sectional research was conducted for 11 months from January 2017 to November 2017 on 93 *E. cloacae* isolates obtained from urine, wound, blood, trachea, sputum, CSF, BAL (Broncho alveolar lavage), and catheter in the teaching hospitals of city of Kermanshah, Iran. The study protocol was approved by ethics committee of Kermanshah University of Medical Sciences (No.: 1395.621). In this study, informed consent was obtained from the patients before sample collection. Only

E. cloacae present in the clinical specimens of inpatient were evaluated and other *Enterobacter* species and environmental samples were excluded.

The procured samples were cultured on the special media of Eosin Methylene Blue (EMB) agar and MacConkey agar (Merck, Germany), in sterile conditions [2]. Then; specific tests like culturing in IMVIC and TSI, Simmons' citrate agar (Himedia CO, India), and indole test were used for identification of *E. cloacae*. Antibiotic susceptibilities were also tested via Kirby-Bauer method on Mueller-Hinton agar (Himedia CO, India), according to Clinical and Laboratory Standards Institute (CLSI) guideline using 12 discs of antibiotics (MAST, U.K.), namely Cefepime (30 µg), Cefpodoxime (30 µg), Cefotaxime (30 µg), Tetracycline (10 µg), Colistin (10 µg), Ceftazidime (30 µg), Chloramphenicol (10 µg), Aztreonam (30 µg), Co-trimoxazole (25 µg), Tobramycin (10 µg), Imipenem (10 µg), and Amoxicillin/Clavulanic acid (20/10 µg) [12].

The standard strain of *Escherichia coli* ATCC 25922 was also used as quality control for antibiogram test. *E. cloacae* isolates, with resistance to three or more antibiotic strains, were further taken into account as MDR strains. Isolates with inhibition zone diameter of approximately 22 mm for Ceftazidime or Cefotaxime were correspondingly investigated for the presence of β-lactamase genes. In addition, ESBL production was confirmed via DDST or Phenotypic Confirmatory Test (PCT). Following the isolation of *E. cloacae* on the Muller Hinton Agar (Merck, Germany), Ceftazidime, Ceftazidime/Clavulanic acid, Cefotaxime, and Cefotaxime/Clavulanic acid (MAST, UK) discs placed. Following 24 hours incubation at 37°C, the strain with zone of inhibition greater than or equal to 5 mm with clavulanic acid, were designated as an ESBL-producing strain of *E. cloacae*, as per CLSI guidelines.

The standard strain of *Klebsiella pneumoniae* ATCC 700603 was also used as the quality control for ESBL-producing strains. Additionally, boiling method for PCR was utilised to extract chromosomal DNA of the isolates. Using specific primers (TakapouZist Co., Iran); the frequency of CTX-M, SHV, and TEM genes was investigated [Table/Fig-1] [13,14]. *K. pneumoniae* ATCC 7881 containing CTX-M, TEM and SHV genes was used as the positive controls. Correspondingly, PCR was carried out individually for all the genes with total volume of 25 µL constituting of 12.5 µL master mix (Sinaclon Co., Iran), 1 µL of each primer, 3 µL DNA and volume was made up with sterile distilled water. The cycling condition of PCR for all three genes consisted of initial denaturation at 94°C for 5 minutes; 35 cycles of denaturation 94°C for 1 minutes, and annealing temperatures at primer-specific temperature, extension at 72°C for 1 minutes followed by a final extension at 72°C for 7 minutes. The amplified PCR products were separated by agarose gel electrophoresis, and the gel was visualised using gel documentation system (UVP, Germany).

Gene	Nucleotide Sequence (5'-3')	Annealing	Product size (bp)
blaCTX-M-F blaCTX-M-R	5'-ACGCTGTGTTAGGAAGTG-3' 5'-TTGAGGCTGGGTGAAGT-3'	58°C, 45 s	759
blaTEM-F blaTEM-R	5'-ATG AGT ATT CAA CAT TTC CG-3' 5'-CCA ATG CTT AAT CAG TGA GG-3'	55°C, 60 s	850
blaSHV-F blaSHV-R	5'-AAG ATC CAC TAT CGC CAG CAG-3' 5'-ATT CAG TTC CGT TTC CCA GCG G-3'	55°C, 30 s	231

[Table/Fig-1]: The nucleotide sequence and annealing temperature of primers used for the detection of ESBL-producing *E. cloacae*.

STATISTICAL ANALYSIS

All statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) software version 20 and Chi-square and Fisher's-tests were used to assess the association between parameters.


RESULTS

The prevalence rate of 93 *E. cloacae* isolates in males and females was 57 (61.3%) and 36 (38.7%); respectively. The age range was 7 to 81 years with mean age 40.70±19.21 years. The frequency of the isolates in the samples was as follow: urine, 33.4% (31 isolates); wound, 19.3% (18 isolates); blood, 17.2% (16 isolates); trachea, 9.7% (9 isolates); sputum, 7.5% (7 isolates); CSF, 5.4% (5 isolates); BAL, 4.3% (4 isolates); and catheter, 3.2% (3 isolates). Maximum number of isolates were resistant to Amoxicillin/Clavulanic acid (97.8%) and Tetracycline and Ceftazidime (60.2%); whereas Colistin had the highest sensitivity (100%) [Table/Fig-2].

Antibiotic	<i>E. cloacae</i> isolated		
	Resistant	Intermediate	Susceptible
Cefotaxime	51 (54.8)	11 (11.8)	31 (33.4)
Cefepime	38 (40.9)	11 (11.8)	44 (47.3)
Ceftazidime	56 (60.2)	11 (11.8)	26 (28)
Cefpodoxime	41 (44.1)	13 (14)	39 (41.9)
Aztreonam	45 (48.4)	10 (10.8)	38 (40.9)
Imipenem	10 (10.8)	9 (9.7)	74 (79.5)
Amoxicillin-Clavulanate	91 (97.8)	1 (1.1)	1 (1.1)
Tobramycin	35 (37.6)	8 (8.6)	50 (53.8)
Tetracycline	56 (60.2)	4 (4.3)	33 (35.5)
Co-trimoxazole	48 (51.6)	9 (9.7)	36 (38.7)
Chloramphenicol	24 (25.8)	5 (5.4)	64 (68.8)
Colistin	0	0	93 (100)

[Table/Fig-2]: Distribution of *E. cloacae* strains isolated from clinical specimens. Prevalence percentages in parentheses

Out of the 93 isolates, 65 isolates (69.9%) were MDR. According to DDST, 55 isolates (59.1%) were phenotypically ESBL positive. Molecularly, CTX-M was the most frequent gene in ESBL positive isolates with a frequency of 26 (47.3%). The frequency of TEM and SHV genes was also reported by 12 (21.8%) and 3 (5.5%), respectively; and three isolates had CTX-M+TEM genes at the same time. Among MDR isolates, the highest frequency of ESBL genes was observed in urine (13 isolates) and in wound (12 isolates) [Table/Fig-3].



[Table/Fig-3]: Frequency of ESBL genes in isolates of MDR *E. cloacae*.

CTX-M was observed to significantly resistant to Cefotaxime (p-value=0.038), Ceftazidime (p-value=0.046), and Imipenem (p-value=0.016), and TEM gene was resistant to Ceftazidime (p-value=0.024) and Chloramphenicol (p-value=0.019) [Table/Fig-4].

Upon PCR, 759 bp bands were obtained for CTX-M gene, 850 bp for TEM gene and 231 bp for SHV gene [Table/Fig-5].

DISCUSSION

Enterobacter species are hospital acquired causative agents of nosocomial infections. ESBL-producing isolates are a major concern because of their resistance to various classes of antibiotics as well as their infectious nature [15]. In contrast to published studies, in the present study the maximum number of *E. cloacae* isolates was found in urine [2,16]. Maximum number of *E. cloacae* isolates


Genes antibiotic	CTX-M (n=26)			TEM (n=12)			SHV (n=3)		
	Resistant	Intermediate	Susceptible	Resistant	Intermediate	Susceptible	Resistant	Intermediate	Susceptible
Cefotaxime	*18	2	6	7	0	5	3	0	0
Cefepime	15	4	6	6	1	5	3	0	0
Ceftazidime	*18	3	5	*9	1	2	0	0	3
Cefpodoxime	16	5	5	7	0	5	2	0	1
Aztreonam	13	6	7	4	3	5	2	0	1
Imipenem	*19	1	6	7	0	5	1	0	2
Amoxicillin-Clavulanate	26	0	0	12	0	0	3	0	0
Tobramycin	17	2	7	7	2	3	1	0	2
Tetracycline	17	2	7	9	2	1	3	0	0
Co-trimoxazole	13	5	8	8	1	3	2	0	1
Chloramphenicol	17	4	5	*9	0	3	2	0	1
Colistin	0	0	26	0	0	12	0	0	3

Significant p-value=*

[Table/Fig-4]: Association between resistance to antibiotics and the presence of ESBL genes in isolates of the *E.cloacae*.

Chi-square and Fisher's tests; *p<0.05 statistically significant

CTX-M: Cefotaximase-Munich, SHV: Sulphydrylvariable, TEM: Temoneira



[Table/Fig-5]: Gel electrophoresis of PCR products of ESBL gene.

- (a) CTX-M: 1- Ladder (100 bp), 2- Negative control, 3- Positive control (759 bp), 4,5- Positive sample (759 bp),
 (b) TEM: 1- Ladder (100 bp), 2-Positive control (850 bp), 3-Positive sample (850 bp), 4- Negative control, and
 (c) SHV: 1- Ladder (100 bp), 2- Positive control (231 bp), 3- Negative control, 4- Positive sample (231 bp).

was observed to be resistant to Amoxicillin/Clavulanate; and these findings were similar to the results of investigations in the cities of Tehran and Qazvin, Iran [17]. Cephalosporins are among the most commonly used antibiotics for treating bacterial infections, and in the present study, 50% *E.cloacae* isolates were resistant to different Cephalosporins with highest resistance to Ceftazidime (60%). Similar results were reported by Malekzadegan Y et al., where the maximum number of isolates was resistant to Cefotaxime [16]. In another Germany based study, 40% of the *E.cloacae* strains were reported to be resistant to broad-spectrum Cephalosporins [10].

In the present study, most susceptibilities were reported to Colistin and Imipenem. In the investigation by Ghorashi Z et al., Colistin and Imipenem were also introduced as the most effective antibiotics [18]. Thus, suggesting that some antibiotics are still useable for effective treatment of these bacterial infections. However, a Jordan based study reported that *E.cloacae* isolates were resistant to Carbapenems, including Meropenem and Imipenem [19]. These discrepancies in the results of drug resistance in multiple studies might be because of difference in bacterial colony as well as their prevalence in hospital environments, drug resistance gene distribution, variance in antibiotic usage pattern, and their administration in patients.

According to the susceptibility antibiotic test, 69.9% (65 isolates) of the isolates were found to be MDR. In another study from the same region; 54 (75%) of the isolates were reported to be MDR isolates, thus confirming the results of the present study [2]. In another Iran-based study, prevalence of MDR was between 26.7% and 91.8%, and the wide range of resistance was attributed to misuse of broad-spectrum antibiotics in hospitals [16,17]. Considering *E.cloacae*, the

main mechanism of drug resistance is production of ESBL. From 93 isolates of *E.cloacae*, 55 (59.1%) were phenotypically positive for ESBL. In contrast to our results, few Iran based studies reported 44.2-100% prevalence rate of ESBL producing *Enterobacter* isolates [16,17,20]. In other countries, such as Brazil, Algeria and India, the prevalence rate of ESBL-producing *Enterobacter* was also reported to be 20%, 47.6% and 73.4% respectively [21-23]. The difference in the results of the ESBL-producing *Enterobacter* isolates can be attributed to diversity in the consumption pattern of various antibiotics, especially ESBL, and implementation of appropriate strategies for management of hospital based infections in treatment centres.

Prior research suggests that CTX-M, TEM, and SHV are the most common ESBL genotypes in *E.cloacae* strains. In the present study, CTX-M gene was found to have highest frequency (47.3%) followed by TEM (21.8%) and SHV (5.5%) genes.

In the study by Ramazan-zadeh R et al., *Enterobacter* isolates obtained from ICUs contained only the CTX-M gene [13]. In another study by Ghanavati R et al., TEM and CTX-M genes were presented as the most commonly reported genes [20]. In different studies from other countries such as Germany, Algeria, and Jordan; CTX-M was reported to be the most frequent gene [10,19,24]. In the study by Bogner C et al., on ESBL positive and third-generation cephalosporins resistant strains of *K. pneumoniae*, *E. coli*, *K. oxytoca*, and *E.cloacae*, CTX-M gene had highest frequency followed by SHV and TEM genes [25]. These findings were contradictory to Moosavian M et al., study on clinical isolates of *Enterobacteriaceae*, where SHV and TEM were the most frequent genes and no CTX-M gene was reported [26]. These variations in the prevalence of ESBLs can be due to differences in the type and the volume of antibiotics used and differences in the collection time of isolates.

In the current study, 3 isolates were observed to have 2 genes (CTX-M+TEM). The simultaneous presence of ESBL genes in a single isolate had been also reported in other studies [19,27]. The presence of combination of genes confines treatment choices and raise challenges in true diagnosis [28]. Since these genes are coded by the plasmids, they can easily transfer in hospital environments; via risk factors such as antibiotic usage, catheter, and person-to-person contact. In the present study, significant association was observed between presence of CTX-M gene and resistance to third-generation Cephalosporin, and the presence of TEM gene and resistance to Ceftazidime. Liu J et al., study showed a significant relationship between antibiotic resistance in *E.cloacae* and presence of ESBL genes [29]. These findings suggest the importance of molecular diagnosis for determining the treatment plan.

LIMITATION

The lack of access to the patient information, and other potential resistant β -lactamase in isolates of *E. cloacae* were not identified. *E. cloacae* isolates should be further examined to determine the frequency of genes resistant to quinolones, aminoglycosides and their relationship to drug resistance patterns.

CONCLUSION

The presence of CTX-M, TEM, and SHV genes in *E. cloacae* indicates their resistance to β -lactam antibiotics. Broad-spectrum β -lactam antibiotics are widely used for treating the gram-negative bacterial infection; however, over the past decade the resistance to this class of antibiotics have increased significantly. This rise in antibiotic-resistant in *E. cloacae* isolates is a serious concern for public health. Therefore, administration of antibiotics should be closely monitored, and both phenotypic and molecular diagnostic techniques should be used to identify the type of genetic resistance to develop effective treatments to prevent emergence of antimicrobial-resistance.

Funding: The present study was supported by Kermanshah University of Medical Sciences, Kermanshah, Iran.

ACKNOWLEDGEMENTS

We would like to express our gratitude to the Deputy of Research and Technology and the Clinical Research Development Unit of the Imam Hospital Kermanshah University of Medical Sciences, Kermanshah, Iran.

REFERENCES

- Mezzatesta ML, Gona F, Stefani S. *Enterobacter cloacae* complex: Clinical impact and emerging antibiotic resistance. *Future Microbiol.* 2012;7(7):887-902.
- Mortazavi SH, Mansouri F, Azizi M, Alvandi A, Karbasfrushan A, Madadi-Goli N, et al. Prevalence of Class I and II Integrons among MDR *Enterobacter cloacae* isolates obtained from clinical samples of children in Kermanshah, Iran. *J Clin Diagn Res.* 2018;12(12):DC13-16.
- Wang GF, Xie GL, Zhu B, Huang JS, Liu B, Kawicha P, et al. Identification and characterization of the *Enterobacter* complex causing mulberry (*Morus alba*) wilt disease in China. *Eur J Plant Pathol.* 2010;126(4):465-78.
- Van den Berg R, Claahsen H, Niessen M, Muijtjens H, Liem K, Voss A. *Enterobacter cloacae* outbreak in the NICU related to disinfected thermometers. *J Hosp Infect.* 2000;45(1):29-34.
- Lee SO, Kim Y, Kim B, Kim MN, Woo JH, Ryu J. Impact of previous use of antibiotics on development of resistance to extended-spectrum cephalosporins in patients with *Enterobacter* bacteremia. *Eur J Clin Microbiol Infect Dis.* 2002;21(8):577-81.
- Matsushima A, Takakura S, Fujihara N, Saito T, Ito Y, Linuma Y, et al. High prevalence of mutators among *Enterobacter cloacae* nosocomial isolates and their association with antimicrobial resistance and repetitive detection. *Clin Microbiol Infect.* 2010;16(9):1488-93.
- Kong KF, Schnepfer L, Mathee K. Beta-lactam antibiotics: From antibiosis to resistance and bacteriology. *APMIS.* 2010;118(1):01-36.
- Azizi M, Mortazavi SH, Etemadimajed M, Gheini S, Vaziri S, Alvandi A, et al. Prevalence of extended-spectrum β -lactamases and antibiotic resistance patterns in *Acinetobacter baumannii* isolated from clinical samples in Kermanshah, Iran. *Jundishapur J Microbiol.* 2017;10(12):e61522.
- Ramphal R, Ambrose PG. Extended-spectrum β -lactamases and clinical outcomes: Current data. *Clin Infect Dis.* 2006;42(Suppl-4):S164-S72.
- Hoffmann H, Stürenburg E, Heesemann J, Roggenkamp A. Prevalence of extended-spectrum β -lactamases in isolates of the *Enterobacter cloacae* complex from German hospitals. *Clin Microbiol Infect.* 2006;12(4):322-30.
- Schlesinger J, Navon-Venezia S, Chmelnitsky I, Hammer-Münz O, Leavitt A, Gold HS, et al. Extended-spectrum β -lactamases among *Enterobacter* isolates obtained in Tel Aviv, Israel. *Antimicrob Agents Chemother.* 2005;49(3):1150-56.
- Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement, CLSI document M100-S20. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania, USA, 2014.
- Ramazanzadeh R, Rouhi S, Hosainzadegan H, Shakib P, Nouri B. Co-occurrence of Extended-Spectrum β -lactamases in isolated *Enterobacter spp.* from patients specimens. *Arch Clin Infect Dis.* 2016;11(3):e26837.
- Salimian Rizi K, Najar Peerayeh S, Bakhshi B, Rahbar M. Prevalence of integrons and antimicrobial resistance genes among clinical isolates of *Enterobacter spp.* from hospitals of Tehran. *Int J Enteric Pathog.* 2015;3(1):8-22531.
- Haidar G, Alkroud A, Cheng S, Churilla TM, Churilla BM, Shields RK, et al. Association between the presence of aminoglycoside-modifying enzymes and in vitro activity of gentamicin, tobramycin, amikacin, and plazomicin against *Klebsiella pneumoniae* carbapenemase- and extended-spectrum- β -lactamase-producing *Enterobacter* species. *Antimicrob Agents Chemother.* 2016;60(9):5208-14.
- Malekzadegan Y, Hadadi M, Ebrahim-Saraie HS, Heidari H, Motamedifar M. Antimicrobial resistance pattern and frequency of multiple-drug resistant *Enterobacter Spp.* at a tertiary care hospital in southwest of Iran. *Journal of Krishna Institute of Medical Sciences (JKIMSU).* 2017;6(2):33-39.
- Peymani Z, Farivar TN, Sanikhani R, Javadi A, Najafipour R. Emergence of TEM, SHV, and CTX-M-extended spectrum β -lactamases and Class 1 integron among *Enterobacter cloacae* isolates collected from hospitals of Tehran and Qazvin, Iran. *Microb Drug Resist.* 2014;20(5):424-30.
- Ghorashi Z, Ghorashi S, Soltani-Ahari H, Nezami N. Demographic features and antibiotic resistance among children hospitalized for urinary tract infection in northwest Iran. *Infection and Drug Resistance.* 2011;4:171-76.
- Adwan G, Rabaya Da, Adwan K, Al-Shebul S. Prevalence of β -lactamases in clinical isolates of *Enterobacter cloacae* in the West Bank-Palestine. *Int J Med Res Health Sci.* 2016;5(7):49-59.
- Ghanavati R, Emaneini M, Kalantar-Neyestanaki D, Maraji AS, Dalvand M, Beigverdi R, et al. Clonal relation and antimicrobial resistance pattern of extended-spectrum β -lactamase- and AmpC β -lactamase-producing *Enterobacter spp.* isolated from different clinical samples in Tehran, Iran. *Rev Soc Bras Med Trop.* 2018;51(1):88-93.
- da Silva Nogueira K, Paganini MC, Conte A, Cogo LL, de Messias Reason IT, da Silva MJ, et al. Emergence of extended-spectrum β -lactamase producing *Enterobacter spp.* in patients with bacteremia in a tertiary hospital in southern Brazil. *Enferm Infec Microbiol Clin.* 2014;32(2):87-92.
- Nedjai S, Barguigua A, Djahmi N, Jamali L, Zerouali K, Dekhil M, et al. Prevalence and characterization of extended spectrum β -lactamases-producing *Enterobacter cloacae* strains in Algeria. *J Infect Dev Ctries.* 2013;7(11):804-11.
- Jain A, Roy I, Gupta MK, Kumar M, Agarwal S. Prevalence of extended-spectrum β -lactamase-producing Gram-negative bacteria in septicaemic neonates in a tertiary care hospital. *J Med Microbiol.* 2003;52(5):421-25.
- labadene H, Messai Y, Ammari H, Ramdani-Bouguessa N, Lounes S, Bakour R, et al. Dissemination of ESBL and Qnr determinants in *Enterobacter cloacae* in Algeria. *J Antimicrob Chemother.* 2008;62(1):133-36.
- Bogner C, Miethke T, Wantia N, Gebhard F, Busch D, Hoffmann R. Differences in ESBL genes between *E. coli*, *Klebsiella spp.* and *Enterobacter Cloacae* Strains. *Int J Clin Med Microbiol.* 2016;1:106.
- Moosavian M, Deiham B. Distribution of TEM, SHV and CTX-M genes among ESBL-producing *Enterobacteriaceae* isolates in Iran. *Afr J Microbiol Res.* 2012;6(26):5433-39.
- Manzur A, Tubau F, Pujol M, Calatayud L, Dominguez MA, Peña C, et al. Nosocomial outbreak due to extended-spectrum- β -lactamases-producing *Enterobacter cloacae* in a cardiothoracic intensive care unit. *J Clin Microbiol.* 2007;45(8):2365-69.
- Gupta V, Garg R, Garg S, Chander J, Attri A. Coexistence of extended spectrum beta-lactamases, AmpC beta-lactamases and metallo- β -lactamases in *Acinetobacter baumannii* from burns patients: A report from a tertiary care centre of India. *Ann Burns Fire Disasters.* 2013;26(4):189.
- Liu J, Li GM, Lin LY, Wu XL, Huang SL, Zhou Y, et al. Association of antibiotic resistance with SHV-12 extended-spectrum β -lactamase in *Enterobacter cloacae*. *Exp Ther Med.* 2016;11(1):269-76.

PARTICULARS OF CONTRIBUTORS:

- Associate Professor, Department of Paediatrics, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- Professor, Department of Infectious Disease, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- Associate Professor, Department of Infectious Disease, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- Associate Professor, Department of Infectious Disease, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- Assistant Professor, Department of Infectious Disease, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- Ph.D. Student of Medical Bacteriology, Department of Microbiology, Pasteur Institute of Iran, Tehran, Iran.
- Research Assistant, Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- Research Assistant, Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Mohsen Azizi,
Department of Microbiology, Faculty of Medicine, Kermanshah University of Medical Sciences, Shirudi blvd, Parastar blvd,
Postal code: 6714869914, Kermanshah, Iran.
E-mail: azizi.mohsenn1363@gmail.com

Date of Submission: **Apr 19, 2019**

Date of Peer Review: **May 23, 2019**

Date of Acceptance: **Jul 05, 2019**

Date of Publishing: **Sep 01, 2019**

FINANCIAL OR OTHER COMPETING INTERESTS: None.